Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DECADES clopidogrel discontinuation after drug-eluting stent study
NL-OMON31060Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Oct 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of clopidogrel in coronary arteriosclerosis, sponsored by Bristol Myers Squibb. Primary endpoint: Mean change in soluble CD40 ligand. Started Oct 2007; status: active, not recruiting.
02
Drugs
clopidogrel
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on NL-OMON31060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON31060.